Eid2 - EP300 interacting inhibitor of differentiation 2

Predicted to enable SMAD binding activity and transcription corepressor activity. Predicted to be involved in several processes, including negative regulation of transcription, DNA-templated; negative regulation of transforming growth factor beta receptor signaling pathway; and transmembrane receptor protein serine/threonine kinase signaling pathway. Predicted to act upstream of or within negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be active in nucleoplasm. Is expressed in brain; embryo; heart; metanephros; and pancreas. Orthologous to human EID2 (EP300 interacting inhibitor of differentiation 2). [provided by Alliance of Genome Resources, Apr 2022]